- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07503821
Synovialvev som en biomarkør i behandlingen av pigmentert villonodulær synovitt (SYVIPRO)
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction. It typically begins between the ages of 30 and 50 and significantly affects patients' functionality. The proliferation is due to somatic mutations in some fibroblastic cells within the tissue, which triggers a massive recruitment of inflammatory cells. The condition is considered a benign tumor of the synovial membrane with a major inflammatory component. Diagnosing PVNS requires synovial tissue analysis, obtained either through surgical excision or guided needle biopsy. This biopsy technique, done as an outpatient procedure, is well tolerated and helps confirm the diagnosis before treatment. Our goal is to better understand this disease and determine if the analysis of synovial tissue could serve as a useful biomarker for patient management in the context of personalized medicine.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, multicentre, open-label study focusing on the collection and analysis of synovial tissue samples from PVNS patients. The study aims to explore the pathophysiology of PVNS and identify prognostic and predictive biomarkers.
Inclusion Criteria: Adults diagnosed with localized or diffuse PVNS, referred for therapeutic management.
Exclusion Criteria: Minors, pregnant or nursing women, individuals under guardianship, patients with severe thrombocytopenia, those on therapeutic anticoagulation, and patients declining participation.
Synovial tissue will be obtained either during surgical intervention (if indicated) or through guided needle biopsy. The biopsy is intended to be diagnostic and will also serve for research purposes. Samples will be analyzed using histological, immunohistochemically, and high-throughput methods.
Patients will be followed one year with two systematic visits (6 months and 1 year after the biopsy). At each visit, they will have a standardized clinical evaluation to assess pain, function and response to treatment. Thereafter, they will be followed as required by the clinical routine over a 4-year period, including clinical assessment and response to treatment.
The primary Outcome is the successful establishment of a patient cohort and synovial biocollection. The secondary Outcomes are the following: Tissue quality, biopsy tolerance, patient acceptability, and the effects of treatments on synovial explants.
Statistical Analysis: The study will include descriptive and predictive analyses, focusing on correlations between synovial abnormalities and clinical progression or treatment response.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Benoit Le Goff, PU-PH
- Telefonnummer: 02 40 08 48 25
- E-post: benoit.legoff@chu-nantes.fr
Studiesteder
-
-
-
Lyon, Frankrike
- Har ikke rekruttert ennå
- Hospices Civils de Lyon
-
Ta kontakt med:
- Fabienne COURY
- Telefonnummer: 08 25 08 25 69
- E-post: fabienne.coury-lucas@chu-lyon.fr
-
Hovedetterforsker:
- Fabienne COURY
-
Nantes, Frankrike
- Rekruttering
- CHU de Nantes
-
Ta kontakt med:
- Benoît LE GOFF
- Telefonnummer: 0240084825
- E-post: benoit.legoff@chu-nantes.fr
-
Hovedetterforsker:
- Benoit LE GOFF
-
Paris, Frankrike
- Har ikke rekruttert ennå
- Hôpital Cochin APHP
-
Hovedetterforsker:
- Jérome AVOUAC
-
Ta kontakt med:
- Jérome AVOUAC
- Telefonnummer: 01 58 41 25 87
- E-post: jerome.avouac@cch.aphp.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient >18 years
- Diagnosis of localized or diffuse villonodular synovitis
- Referred for therapeutic management
- Affiliated with or benefiting from a social security scheme
Exclusion Criteria:
- Pregnant women
- Nursing mothers
- Protected patients: patients under guardianship or curatorship, safeguard of justice
- Patients deprived of liberty
- Curative anticoagulation
- Thrombocytopenia < 50,000 platelets/mm3
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Synovial sampling
Synovial sampling on first visit |
Synovial samples are taken either :
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
antall prøver
Tidsramme: 1 dag
|
1 dag
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
antall bivirkninger
Tidsramme: 1 år
|
1 år
|
|
|
Klyngeanalyse av resultater fra høyt gjennomstrømningseksperimenter
Tidsramme: 1 år
|
1 år
|
|
|
Tissue quality
Tidsramme: 1 month
|
assessed using Krenn's histological score |
1 month
|
|
Patient acceptability
Tidsramme: 1 day
|
using a visual analogue scale |
1 day
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RC24_0068
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .